Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 1;27(2):136-143.
doi: 10.1097/MCO.0000000000000994. Epub 2023 Nov 14.

The 10 essential questions regarding lipoprotein(a)

Karam M Kostner  1 , Gerhard M Kostner  2
Affiliations
Review

The 10 essential questions regarding lipoprotein(a)

Karam M Kostner et al. Curr Opin Clin Nutr Metab Care. .

Abstract

Purpose of review: Lp(a) is one of the most atherogenic lipoproteins, and significant progress has been made to understand its pathophysiology over the last 20 years. There are now selective therapies in late-stage clinical trials to lower Lp(a). Yet there are many outstanding questions about Lp(a). This review outlines 10 of the most burning questions and tries to answer some of them.

Recent findings: Antisense oligonucleotide (ASO) treatment is currently the most advanced therapy to lower plasma Lp(a) by 60-80%. There are, however, also two small molecule medications in early stage of development with similar efficacy.

Summary: This review aims to answer important preclinical and clinical questions about the metabolism and physiological role of Lp(a) and also outlines possible therapeutic approaches with nutraceuticals, currently available lipid-lowering therapies and new medications. In addition, ways are illustrated to use Lp(a) as a marker to better predict cardiovascular risk.

PubMed Disclaimer

References

    1. Kostner K, Kostner GM, Toth PP. Lipoprotein(a). Switzerland: Humana Press; 2023; 1–443 pp.
    1. Berg KA. A new serum type system in man - the Lp system. Acta Pathol Microbiol Scand 1963; 59:369–382.
    1. Gruneis R, Lamina C, Di Maio S, et al. The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A. Atherosclerosis 2022; 349:151–159.
    1. Doi T, Langsted A. Nordestgaard BG lipoproteins, cholesterol, and atherosclerotic cardiovascular disease in East Asians and Europeans. J Atheroscler Thromb 2023; 30:1525–1546.
    1. Singh S, Baars DP, Desai R, et al. Association between Lipoprotein(a) and risk of atrial fibrillation: a systemic review and meta-analysis of Mendelian Randomization studies. Curr Probl Cardiol 2023; 49:102024.